{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:49:06Z","timestamp":1783784946557,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ando.2024.05.015","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T02:17:48Z","timestamp":1718245068000},"page":"197-200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Partial lipodystrophy: Clinical presentation and treatment"],"prefix":"10.1016","volume":"85","author":[{"given":"H\u00e9l\u00e9na","family":"Mosbah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Vatier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Vigouroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2024.05.015_bib0140","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1210\/jc.2011-1159","article-title":"Clinical review: lipodystrophies: genetic and acquired body fat disorders","volume":"96","author":"Garg","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.05.015_bib0145","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.05.015_bib0150","first-page":"907","article-title":"Lipodistrophy: a paradigm for understanding the consequences of \u201coverloading\u201d adipose tissue","volume":"101","author":"Lim","year":"2021","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ando.2024.05.015_bib0155","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.3389\/fendo.2021.803189","article-title":"Molecular and cellular bases of lipodystrophy syndromes","volume":"12","author":"Zammouri","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ando.2024.05.015_bib0160","doi-asserted-by":"crossref","first-page":"R209","DOI":"10.1530\/EJE-15-1131","article-title":"EJE PRIZE 2015: how does insulin resistance arise, and how does it cause disease? Human genetic lessons","volume":"174","author":"Semple","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2024.05.015_bib0165","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11892-022-01485-w","article-title":"Lipodystrophy for the diabetologist\u00a0\u2013\u00a0what to look for","volume":"22","author":"Patni","year":"2022","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.ando.2024.05.015_bib0170","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2337\/db19-0447","article-title":"Clinical and molecular prevalence of lipodystrophy in an unascertained large clinical care cohort","volume":"69","author":"Gonzaga-Jauregui","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.ando.2024.05.015_bib0175","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ejendo\/lvad169","article-title":"Patients\u2019 perspective on the medical pathway from first symptoms to diagnosis in genetic lipodystrophy","volume":"190","author":"Mosbah","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2024.05.015_bib0180","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13023-022-02308-7","article-title":"Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins)","volume":"17","author":"Mosbah","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ando.2024.05.015_bib0185","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1210\/jc.2018-01922","article-title":"Regional body fat changes and metabolic complications in children with Dunnigan lipodystrophy-causing LMNA variants","volume":"104","author":"Patni","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.05.015_bib0190","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1007487","article-title":"Perilipin deficiency and autosomal dominant partial lipodystrophy","volume":"364","author":"Gandotra","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2024.05.015_bib0195","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1210\/jc.2019-00849","article-title":"Diagnostic challenge in PLIN1-associated familial partial lipodystrophy","volume":"104","author":"J\u00e9ru","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.05.015_bib0200","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jacl.2018.07.009","article-title":"MFN2-associated lipomatosis: clinical spectrum and impact on adipose tissue","volume":"12","author":"Capel","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ando.2024.05.015_bib0205","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.molimm.2019.05.011","article-title":"An overview of lipodystrophy and the role of the complement system","volume":"112","author":"Corvillo","year":"2019","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ando.2024.05.015_bib0210","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1530\/EJE-21-0282","article-title":"A recurrent familial partial lipodystrophy due to a monoallelic or biallelic LMNA founder variant highlights the multifaceted cardiac manifestations of metabolic laminopathies","volume":"185","author":"Treiber","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2024.05.015_bib0215","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ando.2019.10.003","article-title":"Lipodystrophic syndromes: from diagnosis to treatment","volume":"81","author":"Sollier","year":"2020","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.ando.2024.05.015_bib0220","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2014-4491","article-title":"Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin","volume":"100","author":"Diker-Cohen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.05.015_bib0225","doi-asserted-by":"crossref","first-page":"e1739","DOI":"10.1210\/clinem\/dgab760","article-title":"Endogenous leptin concentrations poorly predict metreleptin response in patients with partial lipodystrophy","volume":"107","author":"Meral","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.05.015_bib0230","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/03007995.2018.1533459","article-title":"Monogenic forms of lipodystrophic syndromes\u00a0\u2013\u00a0diagnosis, detection, and practical management considerations from clinical cases","volume":"35","author":"Vatier","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ando.2024.05.015_bib0235","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1038\/s41588-023-01535-3","article-title":"Loss of phospholipase PLAAT3 causes a mixed lipodystrophic and neurological syndrome due to impaired PPAR\u03b3 signaling","volume":"55","author":"Schuermans","year":"2023","journal-title":"Nat Genet"},{"key":"10.1016\/j.ando.2024.05.015_bib0240","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.2147\/DMSO.S206053","article-title":"Familial partial lipodystrophy (FPLD): recent insights","volume":"13","author":"Bagias","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.ando.2024.05.015_bib0245","doi-asserted-by":"crossref","first-page":"450","DOI":"10.7326\/L16-0372","article-title":"Sodium-glucose cotransporter 2 inhibitor improves complications of lipodystrophy: a case report","volume":"166","author":"Kawana","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ando.2024.05.015_bib0250","doi-asserted-by":"crossref","first-page":"690996","DOI":"10.3389\/fendo.2021.690996","article-title":"Case report: metreleptin and SGLT2 inhibitor combination therapy is effective for acquired incomplete lipodystrophy","volume":"12","author":"Nagayama","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ando.2024.05.015_bib0255","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13256-016-1175-1","article-title":"Glucagon-like peptide-1 analogues\u00a0\u2013\u00a0an efficient therapeutic option for the severe insulin resistance of lipodystrophic syndromes: two case reports","volume":"11","author":"Oliveira","year":"2017","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.ando.2024.05.015_bib0260","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/dme.13527","article-title":"Insulin secretory defect in familial partial lipodystrophy type 2 and successful long-term treatment with a glucagon-like peptide 1 receptor agonist","volume":"34","author":"Banning","year":"2017","journal-title":"Diabet Med J"},{"key":"10.1016\/j.ando.2024.05.015_bib0265","unstructured":"Recommendations from the Transparency Committee of the French National Authority for Health (HAS) on Metreleptin Therapy: https:\/\/www.has-sante.fr\/portail\/upload\/docs\/evamed\/CT-17322 MYALEPTA PIC INS Avis2 CT17322&17457.pdf and https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2019-09\/myalepta summary ct17457.pdf."},{"key":"10.1016\/j.ando.2024.05.015_bib0270","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.bjps.2011.02.009","article-title":"Surgical management of phenotypic alterations related to the Dunnigan variety of familial partial lipodystrophy","volume":"64","author":"Calderoni","year":"2011","journal-title":"J Plast Reconstr Aesthetic Surg"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426624000702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426624000702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T22:30:35Z","timestamp":1723329035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426624000702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0003426624000702"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2024.05.015","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Partial lipodystrophy: Clinical presentation and treatment","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2024.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}